Overview * Tempest Therapeutics ( TPST ) Q3 net loss narrows to $3.5 mln from $10.6 mln in 2024 * Research and development expenses fell to $0.6 mln from $7.6 mln in Q3 2024 * Company ended Q3 with $7.5 mln in cash, down from $30.3 mln at 2024 year-end Outlook * Tempest continues strategic alternatives process to maximize stockholder...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...

WASHINGTON, Nov 5 (Reuters) - U.S. President Donald Trump told a group of Republican senators at the White House on Wednesday that the ongoing government shutdown is impacting the stock market, as well as airlines and SNAP food benefits for low-income Americans. During the breakfast meeting, Trump again argued for terminating the filibuster, a legislative move that would end long-standing...